These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32823603)

  • 1. The Effect of Different Immunization Cycles of a Recombinant Mucin1-Maltose-Binding Protein Vaccine on T Cell Responses to B16-MUC1 Melanoma in Mice.
    Zhou H; Zhang Z; Liu G; Jiang M; Wang J; Liu Y; Tai G
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
    Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity.
    Jie J; Zhang Y; Zhou H; Zhai X; Zhang N; Yuan H; Ni W; Tai G
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29558459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
    Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
    Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC1 and maltose‑binding protein recombinant fusion protein combined with Bacillus Calmette‑Guerin induces MUC1‑specific and nonspecific anti‑tumor immunity in mice.
    Fang F; Ma J; Ni W; Wang F; Sun X; Li Y; Li Q; Xie F; Wang J; Zhai R; Liu Z; Gao S; Tai G
    Mol Med Rep; 2014 Aug; 10(2):1056-64. PubMed ID: 24912810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene.
    Choi DH; Woo JK; Choi Y; Seo HS; Kim CW
    Mol Med Rep; 2011; 4(5):885-90. PubMed ID: 21725596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
    Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
    Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical toxicity and immunogenicity evaluation of a MUC1-MBP/BCG anti-tumor vaccine.
    Hu B; Wang J; Guo Y; Chen T; Ni W; Yuan H; Zhang N; Xie F; Tai G
    Int Immunopharmacol; 2016 Apr; 33():108-18. PubMed ID: 26896668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-L1 antibody reverses the immune tolerance induced by multiple MUC1-MBP vaccine immunizations by increasing the CD80/PD-L1 ratio, resulting in DC maturation, and decreasing Treg activity in B16-MUC1 melanoma-bearing mice.
    Liu G; Zhang Z; Wu Y; Feng J; Lan Y; Dong D; Liu Y; Yuan H; Tai G; Li S; Ni W
    Int Immunopharmacol; 2023 Aug; 121():110487. PubMed ID: 37364328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
    Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.
    Yang M; Yan Y; Fang M; Wan M; Wu X; Zhang X; Zhao T; Wei H; Song D; Wang L; Yu Y
    Int Immunopharmacol; 2012 Aug; 13(4):408-16. PubMed ID: 22595192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
    Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
    J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses.
    VanLith ML; Kohlgraf KG; Sivinski CL; Tempero RM; Hollingsworth MA
    Int Immunol; 2002 Aug; 14(8):873-82. PubMed ID: 12147624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice.
    Tempero RM; VanLith ML; Morikane K; Rowse GJ; Gendler SJ; Hollingsworth MA
    J Immunol; 1998 Nov; 161(10):5500-6. PubMed ID: 9820526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
    Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
    Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer.
    Guo M; Luo B; Pan M; Li M; Xu H; Zhao F; Dou J
    Int Immunopharmacol; 2020 Nov; 88():106850. PubMed ID: 32777675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1).
    Kohlgraf KG; Gawron AJ; Higashi M; VanLith ML; Shen X; Caffrey TC; Anderson JM; Hollingsworth MA
    Cancer Immunol Immunother; 2004 Dec; 53(12):1068-84. PubMed ID: 15696607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit.
    Lu W; Qiu L; Yan Z; Lin Z; Cao M; Hu C; Wang Z; Wang J; Yu Y; Cheng X; Cao P; Li R
    Oncotarget; 2015 Oct; 6(33):34537-48. PubMed ID: 26417929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.
    Rowse GJ; Tempero RM; VanLith ML; Hollingsworth MA; Gendler SJ
    Cancer Res; 1998 Jan; 58(2):315-21. PubMed ID: 9443411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.